Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment

BACKGROUND: Cisplatin plus pemetrexed combination therapy is considered the standard treatment for patients with advanced, non-squamous, non-small-cell lung cancer (NSCLC). However, advanced NSCLC has a 5-year survival rate of below 10%, which is mainly due to therapy resistance. We previously showe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yanyun, Dorn, Patrick, Liu, Shengchen, Deng, Haibin, Hall, Sean R. R., Peng, Ren-Wang, Schmid, Ralph A., Marti, Thomas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883680/
https://www.ncbi.nlm.nih.gov/pubmed/31798346
http://dx.doi.org/10.1186/s12935-019-1037-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883680/
https://www.ncbi.nlm.nih.gov/pubmed/31798346
http://dx.doi.org/10.1186/s12935-019-1037-1

Ejemplares similares